BE2022C547I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2022C547I2 BE2022C547I2 BE2022C547C BE2022C547C BE2022C547I2 BE 2022C547 I2 BE2022C547 I2 BE 2022C547I2 BE 2022C547 C BE2022C547 C BE 2022C547C BE 2022C547 C BE2022C547 C BE 2022C547C BE 2022C547 I2 BE2022C547 I2 BE 2022C547I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34620101P | 2001-10-19 | 2001-10-19 | |
| PCT/CA2002/001560 WO2003033527A2 (en) | 2001-10-19 | 2002-10-17 | Cyclosporine analogue mixtures and their use as immunomodulating agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2022C547I2 true BE2022C547I2 (da) | 2022-10-19 |
Family
ID=23358378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2022C547C BE2022C547I2 (da) | 2001-10-19 | 2022-10-14 |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US20110092669A1 (da) |
| EP (2) | EP1816138A1 (da) |
| JP (4) | JP2005511538A (da) |
| KR (1) | KR100992850B1 (da) |
| CN (1) | CN100344648C (da) |
| AR (1) | AR036853A1 (da) |
| AT (1) | ATE401339T1 (da) |
| AU (1) | AU2002331510B2 (da) |
| BE (1) | BE2022C547I2 (da) |
| BR (1) | BR0213659A (da) |
| CA (2) | CA2460685C (da) |
| CO (1) | CO5570682A2 (da) |
| CY (1) | CY1108410T1 (da) |
| DE (1) | DE60227686D1 (da) |
| DK (1) | DK1436322T3 (da) |
| EC (3) | ECSP045059A (da) |
| ES (1) | ES2310604T3 (da) |
| FI (1) | FIC20220041I1 (da) |
| FR (1) | FR22C1051I2 (da) |
| HK (1) | HK1062567A1 (da) |
| HR (1) | HRP20040353B1 (da) |
| IL (2) | IL160762A0 (da) |
| LT (1) | LTC1436322I2 (da) |
| MA (1) | MA26337A1 (da) |
| ME (1) | ME00487B (da) |
| MX (1) | MXPA04003624A (da) |
| MY (1) | MY187182A (da) |
| NO (2) | NO331745B1 (da) |
| NZ (1) | NZ531945A (da) |
| PL (1) | PL210697B1 (da) |
| PT (1) | PT1436322E (da) |
| RU (1) | RU2337106C2 (da) |
| SI (1) | SI1436322T1 (da) |
| TN (1) | TNSN04069A1 (da) |
| UY (1) | UY27502A1 (da) |
| WO (1) | WO2003033527A2 (da) |
| ZA (1) | ZA200402270B (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1436321E (pt) | 2001-10-19 | 2006-10-31 | Isotechnika Inc | Sintese de analogos de ciclosporina |
| MXPA04003624A (es) * | 2001-10-19 | 2004-12-06 | Isotechnika Inc | Mezclas analogas de ciclosporina y su uso como agentes inmunolomoduladores. |
| TW200505946A (en) * | 2003-04-08 | 2005-02-16 | Hoffmann La Roche | Process for preparation of cyclosporin a analog |
| BRPI0517207A (pt) * | 2004-12-17 | 2008-09-30 | Isotechnika Inc | composto isolado, metabólito isolado de ciclo {{(e)- e (z)- (2s,3r,4r)-3-hidróxi-4-metil-2-(metilamino)-6,8-nonadien oil}-l-2-aminobutiril-n-metil-glicil-n-metil-l-leucil-l-v alil-n-metil-l-leucil-l-alanil-d-alanil-n-metil-l-leucil- n-metil-l-leucil-n-metil-l-valil} (isa247) e os sais e solvatos farmaceuticamente aceitáveis dos mesmos, método de preparação de metabólitos de isa247 in vitro, método de produção de um metabólito hidroxilado de isa247, metabólito hidroxilado isolado de isa247, metabólito hidroxilado isolado, método de produção de um metabólito de epóxido de isa247 in vitro, metabólito isolado de epóxido de isa247, metabólito isolado de epóxido, método de produção de um metabólito de diol de isa247 in vitro, metabólito de diol isolado de isa247, metabólito de diol isolado, método de produção de um metabólito de diol de isa247, método de produção de um metabólito de diol de isa247 e composição farmacêutica |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| CN101918019B (zh) | 2007-10-08 | 2014-11-26 | 奥里尼亚制药有限公司 | 包含钙调神经磷酸酶抑制剂或mTOR抑制剂的眼科组合物 |
| CN102458370A (zh) | 2009-06-09 | 2012-05-16 | 卢克斯生物科技公司 | 用于眼科用途的表面药物递送系统 |
| GB0912584D0 (en) * | 2009-07-20 | 2009-08-26 | Ucl Business Plc | Cyclosporin conjugates |
| AU2011342284C1 (en) | 2010-12-15 | 2017-07-13 | Contravir Pharmaceuticals, Inc. | Cyclosporine analogue molecules modified at amino acid 1 and 3 |
| GB201222455D0 (en) * | 2012-12-13 | 2013-01-30 | Perioc Ltd | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease |
| US20210104302A1 (en) * | 2016-11-30 | 2021-04-08 | Schrödinger, Inc. | Graphical user interface for chemical transition state calculations |
| WO2018106959A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018106928A1 (en) | 2016-12-08 | 2018-06-14 | Contravir Pharmaceuticals, Inc. | Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3 |
| AU2017378406A1 (en) | 2016-12-14 | 2019-06-13 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| US10286036B2 (en) * | 2017-05-12 | 2019-05-14 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| EP4201952A1 (en) | 2021-12-21 | 2023-06-28 | Curia Spain, S.A.U. | Process for the controlled synthesis of voclosporin |
| WO2024052941A1 (en) * | 2022-09-09 | 2024-03-14 | Dr. Reddy's Laboratories Limited | Improved process for the preparation of voclosporin |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4278545A (en) * | 1979-09-12 | 1981-07-14 | The Bendix Corporation | Apparatus for separating solids and liquid components |
| CH670644A5 (da) * | 1986-12-18 | 1989-06-30 | Lonza Ag | |
| US5162540A (en) * | 1986-12-18 | 1992-11-10 | Lonza Ltd. | Process for the production of (+) biotin |
| EP0296122B1 (en) * | 1987-06-17 | 1993-09-29 | Sandoz Ag | Cyclosporins and their use as pharmaceuticals |
| US5972630A (en) * | 1991-08-19 | 1999-10-26 | Dade Behring Marburg Gmbh | Homogeneous immunoassays using enzyme inhibitors |
| US5750510A (en) * | 1997-04-04 | 1998-05-12 | Abbott Laboratories | 3-descladinose-2,3-anhydroerythromycin derivatives |
| US5939406A (en) * | 1997-07-21 | 1999-08-17 | Wisconsin Alumni Research Foundation | 18-substituted-19-nor-vitamin D compounds |
| ES2256959T3 (es) * | 1997-10-08 | 2006-07-16 | Isotechnika,Inc. | Analogos de ciclosporina deuterados y no deuterados y su uso como agentes inmunomoduladores. |
| PT1436321E (pt) * | 2001-10-19 | 2006-10-31 | Isotechnika Inc | Sintese de analogos de ciclosporina |
| MXPA04003624A (es) * | 2001-10-19 | 2004-12-06 | Isotechnika Inc | Mezclas analogas de ciclosporina y su uso como agentes inmunolomoduladores. |
-
2002
- 2002-10-17 MX MXPA04003624A patent/MXPA04003624A/es active IP Right Grant
- 2002-10-17 IL IL16076202A patent/IL160762A0/xx unknown
- 2002-10-17 CA CA2460685A patent/CA2460685C/en not_active Expired - Lifetime
- 2002-10-17 EP EP07106871A patent/EP1816138A1/en not_active Withdrawn
- 2002-10-17 UY UY27502A patent/UY27502A1/es not_active Application Discontinuation
- 2002-10-17 JP JP2003536265A patent/JP2005511538A/ja not_active Withdrawn
- 2002-10-17 ME MEP-2008-780A patent/ME00487B/me unknown
- 2002-10-17 BR BR0213659-7A patent/BR0213659A/pt not_active IP Right Cessation
- 2002-10-17 AT AT02767028T patent/ATE401339T1/de active
- 2002-10-17 PL PL370501A patent/PL210697B1/pl unknown
- 2002-10-17 WO PCT/CA2002/001560 patent/WO2003033527A2/en active IP Right Grant
- 2002-10-17 AU AU2002331510A patent/AU2002331510B2/en not_active Expired
- 2002-10-17 KR KR1020047005721A patent/KR100992850B1/ko active IP Right Grant
- 2002-10-17 MY MYPI20023885A patent/MY187182A/en unknown
- 2002-10-17 CN CNB02820798XA patent/CN100344648C/zh not_active Expired - Lifetime
- 2002-10-17 AR ARP020103918A patent/AR036853A1/es not_active Application Discontinuation
- 2002-10-17 PT PT02767028T patent/PT1436322E/pt unknown
- 2002-10-17 CA CA2727642A patent/CA2727642C/en not_active Expired - Lifetime
- 2002-10-17 ES ES02767028T patent/ES2310604T3/es not_active Expired - Lifetime
- 2002-10-17 DK DK02767028T patent/DK1436322T3/da active
- 2002-10-17 NZ NZ531945A patent/NZ531945A/en not_active IP Right Cessation
- 2002-10-17 SI SI200230742T patent/SI1436322T1/sl unknown
- 2002-10-17 EP EP02767028A patent/EP1436322B1/en not_active Expired - Lifetime
- 2002-10-17 RU RU2004110941/04A patent/RU2337106C2/ru active
- 2002-10-17 DE DE60227686T patent/DE60227686D1/de not_active Expired - Lifetime
-
2004
- 2004-03-05 IL IL160762A patent/IL160762A/en active IP Right Grant
- 2004-03-23 ZA ZA2004/02270A patent/ZA200402270B/en unknown
- 2004-03-26 MA MA27598A patent/MA26337A1/fr unknown
- 2004-04-14 EC EC2004005059A patent/ECSP045059A/es unknown
- 2004-04-14 EC EC2004005061A patent/ECSP045061A/es unknown
- 2004-04-14 EC EC2004005060A patent/ECSP045060A/es unknown
- 2004-04-16 TN TNP2004000069A patent/TNSN04069A1/en unknown
- 2004-04-19 CO CO04035672A patent/CO5570682A2/es not_active Application Discontinuation
- 2004-04-19 HR HRP20040353AA patent/HRP20040353B1/hr not_active IP Right Cessation
- 2004-05-14 NO NO20042029A patent/NO331745B1/no not_active IP Right Cessation
- 2004-07-22 HK HK04105424A patent/HK1062567A1/xx not_active IP Right Cessation
-
2008
- 2008-10-13 CY CY20081101130T patent/CY1108410T1/el unknown
-
2009
- 2009-06-11 JP JP2009140608A patent/JP5272140B2/ja not_active Expired - Lifetime
-
2010
- 2010-07-02 JP JP2010151859A patent/JP2011006417A/ja active Pending
- 2010-12-23 US US12/977,602 patent/US20110092669A1/en not_active Abandoned
-
2013
- 2013-01-31 JP JP2013017448A patent/JP2013136597A/ja active Pending
-
2014
- 2014-03-18 US US14/217,827 patent/US20140288266A1/en not_active Abandoned
-
2022
- 2022-10-14 FI FIC20220041C patent/FIC20220041I1/fi unknown
- 2022-10-14 BE BE2022C547C patent/BE2022C547I2/nl unknown
- 2022-10-14 LT LTPA2022521C patent/LTC1436322I2/lt unknown
- 2022-10-14 NO NO2022042C patent/NO2022042I1/no unknown
- 2022-10-14 FR FR22C1051C patent/FR22C1051I2/fr active Active